The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma

Ann S. LaCasce, MD
Published Online: 11:03 PM, Mon December 8, 2014
Ann S. LaCasce, MD, assistant professor of medicine, Harvard Medical School, lymphoma program, Dana-Farber Cancer Institute, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.

Clinical Pearls

  • The study analyzed 53 patients with Hodgkin lymphoma who were in first relapse or had primary refractory disease after initial therapy.
  • Patients were treated with brentuximab vedotin in combination with bendamustine.
  • The overall response rate was 96%.
  • 83% of patients achieved a complete remission.
  • Some unexpected infusion-related toxicity was observed.

<<< Go back to the ASH conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.